Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) (IFM2010-02)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
University Hospital, Lille
ClinicalTrials.gov Identifier:
NCT01745640
First received: October 29, 2012
Last updated: November 19, 2014
Last verified: November 2014
  Purpose

The purpose of this study is to determine the efficacy and toxicity profile of Pomalidomide and Dexamethasone in relapsed or refractory Multiple Myeloma patients with deletion 17p or translocation (4;14)


Condition Intervention Phase
Multiple Myeloma
Drug: POMALIDOMIDE
Drug: Dexamethasone
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter Open Label Phase II Study of Pomalidomide and Dexamethasone in Progressive Relapsed or Refractory Multiple Myeloma Patients With Deletion 17p or Translocation (4;14) Adverse Karyotypic Abnormalities-IFM2010-02

Resource links provided by NLM:


Further study details as provided by University Hospital, Lille:

Primary Outcome Measures:
  • Time to disease progression (from the date of the first dose to the date of the first observation of disease progression) [ Time Frame: The final analysis of disease progression will be run when at least 29 events will occur (expected average of 32months ). ] [ Designated as safety issue: No ]
    The time to progression (TTP) is the time from the start of treatment to the first documentation of disease progression or death from any cause during study, whichever occurs earlier.The Kaplan-Meier procedures will be used to characterize the time-to-event curves (TTP, OS, response duration and EFS) when there is censoring; univariate summary statistics will be provided for time to response.


Secondary Outcome Measures:
  • Safety of pomalidomide and dexamethasone [ Time Frame: for the first 15 patients included at time they end cycle 1 (an expected average of 6 months from the first inclusion) ] [ Designated as safety issue: Yes ]

    All patients who receive at least one dose of study medication will be included in the safety analyses. Adverse events, vital sign measurements, clinical laboratory information, and concomitant medications will be tabulated and summarized when appropriate.

    Patient incidence rates of all Adverse Events will be tabulated by body system class, preferred term, and severity grades whenever possible and will be provided with the number and percentage of subjects with adverse events


  • Overall Response rate (Partial Response and better), Very Good Partial Response (VGPR) + Complete Response (CR) rate and stringent Complete Response (sCR) rate to pomalidomide and dexamethasone in MM patients [ Time Frame: The final analysis of disease progression will be run when at least 29 events will occur (expected average of 32months from beginning of study ). ] [ Designated as safety issue: No ]
    Response rate (Partial Response and better) to pomalidomide and Dexamethasone in the studied population will be determined using International Myeloma Working Group (IMWG) response criteria. VGPR + CR rate and sCR rate will also be determined using IMWG [1]

  • Time to response and Response duration of pomalidomide and dexamethasone. [ Time Frame: The final analysis of disease progression will be run when at least 29 events will occur (expected average of 32months from beginning of study ). ] [ Designated as safety issue: No ]
    A responder will be any patient who shows at least a partial response (PR) at any time during the study. For responders, time to response and response duration will be analyzed. Time to response is the time from the start of treatment to the first documentation of response (either PR or better). Duration of response is the time from the first PR or better to the first documentation of disease progression. Following the completion of the first cycle, efficacy assessments will be given every 28 days as long as they stay on treatment up to 12 months then every 2 months until progression.

  • Overall Survival of pomalidomide and dexamethasone and event free survival [ Time Frame: The final analysis of disease progression will be run when at least 29 events will occur (expected average of 32months from beginning of study ). ] [ Designated as safety issue: No ]
    The median overall survival for patients with MM is approximately 4-5 years, and MM remains an incurable disease. Overall survival (OS) is the time from the start of treatment to date of last news or death from any cause. Event free survival (EFS) is the time from the start of treatment to the date of progression, death, or other cause of discontinuation of study drug, including serious drug toxicity.

  • Response and Time to disease progression with regards to cytogenetic abnormalities in the bone marrow tumor plasma cells [ Time Frame: The final analysis of disease progression will be run when at least 29 events will occur (expected average of 32months from beginning of study ). ] [ Designated as safety issue: No ]
    Response rate (Partial Response and better) to pomalidomide and Dexamethasone in the studied population will be determined using International Myeloma Working Group (IMWG) response criteria. VGPR + CR rate and sCR rate will also be determined using IMWG [1]


Estimated Enrollment: 55
Study Start Date: January 2012
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: POMALIDOMIDE and dexamethasone treatment
All patients will receive pomalidomide (4 mg/day per os) and dexamethasone (40/20 mg/wk per os) during 21 day/28 day cycle
Drug: POMALIDOMIDE
hard capsule 4mg/day, oral route, from day 1 to 21 per 28 days cycle
Other Name: 4mg/day, oral route, from day 1 to 21 per 28 days cycle
Drug: Dexamethasone
40mg (if patient <75 years)/20mg weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle
Other Name: weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

inclusion criteria:

  • Able to understand and voluntarily sign an informed consent form
  • Age >18 years
  • Life expectancy > 6 months.
  • Patients must have a Symptomatic and Progressive MM
  • Patients must have a clearly detectable and quantifiable monoclonal M-component value
  • Eastern Cooperative Oncology Group performance status score of 0, 1, or 2
  • Adequate bone marrow function, with no transfusion within 5 days prior to treatment.
  • Adequate organ function
  • Wash out period of at least 2 weeks from previous antitumor therapy or any investigational treatment.
  • Able to take antithrombotic medicines
  • Subjects affiliated with an appropriate social security system.
  • Agree to abstain from donating blood while taking study drug therapy and for at least 28 days following discontinuation of study drug .
  • Female subjects of childbearing potential (FCBP) (*) must:

Understand the potential teratogenic risk of the treatment and take the relative precaution mentioned in the protocol, in the Pomalidomide information sheet Agree to abstain from breastfeeding during study participation and for at least 28 days after study drug discontinuation

  • For female NOT of childbearing potential, pomalidomide is contraindicated unless the exceptions mentioned in the protocol
  • Understand the hazards and necessary precautions associated with the use of pomalidomide
  • Male subjects must:
  • Understand the potential teratogenic risk and take the relative precaution mentioned in the protocol, in the Pomalidomide information sheet

Exclusion criteria :

  • Patient that will require allogeneic or autologous transplantation following pomalidomide dexamethasone treatment while in the same course.
  • Any other uncontrolled medical condition or comorbidity that might interfere with subject&apos;s participation
  • Use of any other experimental drug or therapy within 15 days of screening.
  • Patients with renal failure that require dialysis and patients with creatinine clearance < 50 mL/min
  • Prior history of malignancies, other than multiple myeloma, unless the patients has been free of the disease for ≥3 years. Excepted those mentioned in the protocol.
  • Prior local irradiation within two weeks before screening
  • Ongoing active infection, especially ongoing pneumonitis
  • Ongoing Cardiac dysfunction
  • Inability or unwillingness to comply with birth control requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01745640

Locations
France
CHRU - Hôpital du Bocage
Angers, Angers cedex 01, France, 49033
CHRU-Hôpital Sud Amiens
Amiens, France, 80054
Centre Hospitalier de la côte basque
Bayonne, France, 64109
Centre Hospitalier BLOIS
Blois, France, 41016
Hôpital Avicenne
BOBIGNY cedex, France, 93009
Chru Caen
Caen, France, 14033
CHU DIJON, Hôpital d'Enfants
Dijon, France, 21000
Hospitalier Général DUNKERQUE
Dunkerque, France, 59 385
CHRU, Hôpital A.Michallon
Grenoble, France, 38043
Centre hospitalier départemental La Roche sur Yon
La Roche sur Yon, France, 85025
Chru Lille
Lille, France, 59037
Institut Paoli Calmette,
Marseille, France, 13273
CHRU, Hôtel Dieu
Nantes, France, 44035
Centre de NICE 1/ Hôpital Archet
Nice, France, 06 202
Centre de NICE 2/ Hôpital Archet
Nice, France, 06202
CHU - Hôpital St Antoine,
Paris, France, 75571
Hôpital Saint-Louis
Paris, France, 75475
Hôpital Haut-Leveque
PESSAC cedex, France, 33604
Centre Hospitalier Lyon Sud -2
Pierre Benite, France, 69495
Centre Hospitalier Lyon Sud -1
Pierre Benite, France, 69495
CHRU POITIERS-Hôpital Jean Bernard
Poitiers, France, 86021
Hôpital Robert Debré, CHU Reims
Reims, France, 51092
CHRU RENNES 1, Hôpital Sud
Rennes, France, 35056
CHRU RENNES 2, Hôpital Pontchaillou
Rennes, France, 35033
CHRU, Hôpital Purpan
Toulouse, France, 31059
CHRU- Hôpital Bretonneau
Tours, France, 37044
CHRU, Hôpitaux de Brabois
Vandoeuvre, France, 54511
Sponsors and Collaborators
University Hospital, Lille
Celgene Corporation
Investigators
Principal Investigator: Xavier LELEU, PHD CHRU de Lille
  More Information

No publications provided

Responsible Party: University Hospital, Lille
ClinicalTrials.gov Identifier: NCT01745640     History of Changes
Other Study ID Numbers: 2010_52, 2011-002081-20
Study First Received: October 29, 2012
Last Updated: November 19, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
United States: Food and Drug Administration

Keywords provided by University Hospital, Lille:
Multiple myeloma
dexamethasone
pomalidomide
response
safety
del 17p
t 4-14

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Pomalidomide
Thalidomide
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Anti-Inflammatory Agents
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 20, 2014